Literature DB >> 8556969

Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts.

S Dawe1, J A Gray.   

Abstract

Based upon findings relating to the reinstatement of responding from the animal laboratory, the present study investigated whether methadone, a synthetic opiate, would prime the desire to use heroin for its pleasant effect (i.e. for positive reinforcement) compared to clonidine, a non-opiate drug, in detoxifying opiate addicts (n = 16). In-patient opiate addicts were tested at maximum withdrawal and minimal withdrawal, and self-reported desire to use heroin (i) for its pleasant effect (positive craving) and (ii) to alleviate an unpleasant feeling or mood (negative craving) was recorded before drug administration, immediately after drug administration and on 4 further occasions, 15 min apart. In addition, self-reported rating of opiate withdrawal symptoms were also recorded. Although elevated in the methadone group, the difference between methadone and clonidine groups in positive craving did not reach statistical significance. Interpretation of the data is complicated by elevated baselines of positive craving in the methadone group at minimum withdrawal. Measures of negative craving and self-reported withdrawal symptoms showed a similar pattern of decline, and were significantly correlated at maximum withdrawal, thereby providing evidence from substance misusers themselves that the constructs of positive and negative reinforcement can be differentiated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8556969     DOI: 10.1016/0376-8716(95)01159-8

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  5 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Prediction and Prevention of Prescription Drug Abuse: Role of Preclinical Assessment of Substance Abuse Liability.

Authors:  Julie A Marusich; Timothy W Lefever; Scott P Novak; Bruce E Blough; Jenny L Wiley
Journal:  Methods Rep RTI Press       Date:  2013-07

Review 3.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

Review 4.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 5.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.